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Background: Although epidermal growth factor receptor (EGFR) inhibitor treatment showed modest response in
several clinical trials in esophageal squamous cell carcinoma (ESCC) patients, it has been reported that the
frequency of EGFR mutations varied largely. The aim of this study was to investigate the existence of EGFR
mutations in Chinese esophageal squamous cell carcinomas.
Methods: Formalin-fixed paraffin-embedded surgically resected tumor samples were obtained from 127 randomly
selected Chinese patients with ESCC. The most common EGFR mutations, including in-frame deletions in exon 19
and base substitutions in exon 21, were detected by denaturing high performance liquid chromatography (DHPLC)
and direct sequencing simultaneously. K-RAS mutations in codons 12 and 13 were detected by direct sequencing.
Results: In this study, L858R missense mutations of the EGFR gene were found in 8 out of 127 patients (6.3%) by
DHPLC but no mutation was observed by direct sequencing. In addition, K-RAS mutation was detected in 2 out of
127 (1.6%) patients by direct sequencing.
Conclusions: The incidence of EGFR mutations was relatively high using DHPLC method but no mutation with
direct sequencing in Chinese ESCC patients.
Keywords: Epidermal growth factor receptor, Esophageal squamous cell carcinoma, Denaturing high performance
liquid chromatographyBackground
Esophageal squamous cell carcinoma (ESCC) is the major
histological type of esophageal cancer and is one of the
most aggressive malignant tumors in China [1]. Despite
remarkable advances in multimodal therapies, patient
prognosis remains poor, even for those whose carcinomas
have been completely resected [2,3]. The limited improve-
ment in treatment outcomes by conventional therapies
urged us to seek innovative strategies for treating ESCC,
especially those that are molecularly targeted. One of the
most promising targets is the inhibition of the epidermal
growth factor receptor (EGFR) by monoclonal antibodies
(for example, cetuximab, panitumumab) or small molecule
tyrosine kinase inhibitors (for example, erlotinib, gefitinib)* Correspondence: guomin616616@163.com
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reproduction in any medium, provided the or[4,5]. The EGFR is a member of the ErbB receptor tyrosine
kinase family and plays an important role in cell cycle pro-
gression, angiogenesis, metastasis, and protection from
apoptosis. Studies have showed that the kinase domain
mutations of the EGFR gene in the non-small-cell lung
cancer (NSCLC) tissues correlate with clinical responses
to gefitinib. Most of the mutations were located in exons
19 and 21 of the EGFR gene including in-frame deletions
in exon 19 and amino acid substitutions in exon 21 [4-6].
On the other hand, V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (K-RAS) is a critical downstream ef-
fector of the EGFR pathway. K-RAS mutations are associ-
ated with intrinsic tyrosine kinase inhibitor (TKI) resistance
in patients with lung cancer [7,8]. Thus, molecular diagno-
sis of these mutations is increasingly important in making
therapeutic decisions.
Phase I and II clinical trials of the small-molecule TKIs
of EGFR, erlotinib and gefitinib, in ESCC treatment are. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in patients with esophageal cancers [9-11]. However, it
remains unclear whether EGFR mutations in esophageal
cancer predict benefits from treatment with EGFR inhib-
itors. Several studies have investigated the status of
EGFR mutations in esophageal carcinoma and appear to
suggest that EGFR mutations in esophageal carcinoma
are rare but do exist [12-16]. Among these, one report
carried out in Chinese patients found EGFR mutations
in 14% of tumors, which is relatively higher than other
regional research results. Furthermore, the authors used
the scorpion amplification refractory mutation system
(Scorpion-ARMS), a high sensitivity method for the
identification of mutations. Therefore, it is worthwhile
exploring whether different etiological factors or sensi-
tivity methods contributed to the higher frequency of
EGFR mutations in ESCC [16]. In this study, we investi-
gated the existence of hot spot mutations in exon 19
and 21 of EGFR in Chinese ESCC patients with another
sensitive method based on denaturing high performance
liquid chromatography (DHPLC) as well as direct se-
quencing, simultaneously, and screened the status of




A total of 127 consecutive patients with ESCC who were
undergoing curative resection at Beijing Friendship Hos-
pital of Capital Medical University between April 2008
and December 2011 were enrolled in this study. Tumor
staging was done by the American Joint Committee on
Cancer Staging Manual (7th edition). Written informed
consent was obtained from each subject, and the study
procedures were approved by the institutional review
board of Capital Medical University.
DNA extraction
DNA was extracted from the tumor tissue sections (5-μm
thickness) micro-dissected from formalin-fixed paraffin-
embedded tumor specimens. Genomic DNA was isolated
by digestion with proteinase K, followed by phenol-
chloroform extractions [17].
PCR and DNA sequencing
Three pairs of primers targeting exons 19 and 21 of the
EGFR gene, as well as the K-RAS gene, were designed by
using Primer Premier 5.0 (PREMIER Biosoft International,
CA, USA). The sequences were as follows: exon 19: for-
ward 5′- TGGTAACATCCACCCAGAT-3′, reverse 5′-
CAGAGCAGCTGCCAGACATGAG-3′; exon 21: forward
5′- TACAGTGGATATAGAAAGGAC-3′, reverse 5′- TGC
TTATTTCATCTCAATCCTACGCTT-3′; K-RAS: forward
5′- CGCCGTTAACCTTATGTGTGACATGTTCTAA-3′,reverse 5′- CGCCGCTTTATCTGTATCAAAGAATGGT
CCT-3′. PCR amplification was carried out on an ABI
9700 PCR thermal cycler (Applied Biosystems, Foster City,
CA, USA) in a 50 uL reaction system containing 1 × buffer
(10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 50 mM
KCl, and 0.1% gelatin/ml), 200 mM each of the four
deoxynucleotide triphosphates, 0.5 mM of each primer, 5%
DMSO (Sigma-Aldrich, St. Louis, MO, USA), 1 unit of Taq
polymerase (Takara Bio, Hotsu, Japan) and 100 ng template.
The PCR cycling conditions consisted of an initial denatur-
ation step at 94°C for 5 minutes, followed by 35 cycles of
94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30
seconds, and a final extension step at 72°C for 10 minutes.
Reaction products were direct sequencing with an ABI
PRISM 3100 sequencer (Applied Biosystems) following the
manufacturer’s protocol.
Denaturing high performance liquid chromatography-
based method for the detection of EGFR exon 19 and 21
mutations
EGFR exon 19 deletion mutations were analyzed using
DHPLC as described previously [18]. The most com-
mon mutation, L858R in exon 21 of EGFR, was detected
using the restriction enzyme enriched mutation method
as described except replacing polyacrylamide gel elec-
trophoresis with DHPLC in the analyzing process [19].
Similar to Scorpion-ARMS, the detection sensitivity of
the DHPLC method could reach approximately 1% mu-
tant alleles [18,19].
Results
EGFR exons 19 and 21 mutation in esophageal squamous
cell carcinoma
No mutations in exons 19 and 21 of the EGFR were ob-
served in the 127 patient tumor samples using direct se-
quencing analysis. However, a total of 8 samples out of
127 detected the same EGFR mutation (p.L858R) in exon
21 when DHPLC-based high sensitive methods were per-
formed to detect EGFR mutations (Figure 1). No mutation
was detected in exon 19 by either method.
K-RAS mutation in esophageal squamous cell carcinoma
A heterozygous mutation of the K-RAS gene (c.35 G > T;
p.Gly12Cys) was detected in 2 out of the 127 patients
(1.6%) by sequencing analysis (Figure 2), despite low level
mutations. No mutation was found in codon 13.
Discussion
In NSCLC, a growing number of studies demonstrated
that patients with EGFR mutations, mainly deletions in
exon 19 and L858R mutation in exon 21, would benefit
from EGFR-TKI treatment, particularly among those of
Asian ethnicity [5,18,20]. Furthermore, a few clinical stud-
ies of advanced esophageal cancer treatment by gefitinib
Figure 1 Representative result of denaturing high performance liquid chromatography and sequencing for EGFR L858R mutations.
(A) L858R missense mutations in exon 21 were found using the denaturing high performance liquid chromatography-based method. A single
peak on the left (123 bp) indicates mutant alleles, and that on the right indicates wild-type alleles at about 138 bp. (B) No mutations were
detected under sequencing conditions.
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studies have investigated the status of EGFR mutations in
esophageal carcinoma and they mostly showed a very low
frequency of EGFR-activating mutations [12-16,22-24]. It
should be noted that EGFR mutations were detected by a
high sensitive method instead of direct sequencing only inFigure 2 Mutations in the K-RAS gene in esophageal squamous cell c
(B, C) Heterozygous GGT→ GTT mutation in the second position of codona few studies, and one of them reported relatively higher
frequency of EGFR mutations in 14% of tumors including
G719X missense mutation (n = 1), in-frame deletion (n =
2), and L858R missense mutation (n = 5) [16].
In this study, a high sensitivity DHPLC-based method,
as well as conventional direct sequencing, were performedarcinoma samples. (A) No mutation in codons 12 and 13.
12 in two samples (arrow).
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exon 21 of the EGFR gene in 127 Chinese ESCC patients,
respectively. The results showed that 7% of the ESCC
samples harbored EGFR mutations detected by DHPLC
compared with no observed EGFR mutation by direct
sequencing, which may be partly attributed to the high
sensitivity of DHPLC in mutation detection. Our findings
were consistent with a previous study in which Scorpion-
ARMS, another high sensitivity method to detect EGFR
mutation, was performed to screen EGFR mutation in
Chinese ESCC patients [16]. Furthermore, the status of
KRAS gene mutationwas detected by direct sequencing
and showed relatively low frequency (1.6%); this was in
line with previous studies in which the incidence of K-RAS
gene mutations ranges between 0 and 16% [16,25,26]. To-
gether with other findings, our data indicated that EGFR
mutations exist in esophageal carcinoma at low levels,
which is difficult to detect by conventional DNA sequen-
cing. This partly explains the variant frequency of EGFR
mutations in several studies with different sensitivity me-
thods and complicates the efficacy of targeted therapies in
some patients except for etiological factors [13,16,22]. The
existence of low levels of EGFR mutation in ESCC indi-
cates the presence of intra-tumor EGFR mutational het-
erogeneity, suggesting high sensitivity method should be
preferred for studies exploring the correlation between
EGFR mutations and TKI treatment in ESCC patients.Conclusion
Our findings demonstrated that the incidence of EGFR
mutations in Chinese patients with ESCC was relatively
higher than that of previous reports, partly as a result of
mutation detection with a high sensitivity method. In
line with other studies, it seemed that a high sensitivity
method should be preferred when the status of EGFR
mutations need to be explored in clinical trials of TKI in
ESCC treatment.
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